Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

Cancer Science

Volumn 102, Issue 9, 2011, Pages 1687-1692

  Ogura, Michinori ^a   Ando, Kiyoshi ^b   Taniwaki, Masafumi ^c   Watanabe, Takashi ^d   Uchida, Toshiki ^a   Ohmachi, Ken ^b   Matsumoto, Yosuke ^c   Tobinai, Kensei ^d  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BENDAMUSTINE; CHLORPHENIRAMINE MALEATE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HYPERURICEMIA; HYPOKALEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LOW BACK PAIN; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; THRUSH; TRANSFORMED LYMPHOMA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; REMISSION INDUCTION;

EID: 80051807929     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01994.x     Document Type: Article

References (27)

1. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7: 415-21.
2. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-17.
3. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55: 109-13.
4. Pönisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205-12.
5. von Minckwitz G, Chernozemsky I, Sirakova L et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16: 871-7.
6. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90: 1287-8.
7. Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1285-9.
8. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-9.
9. Ogura M, Uchida T, Taniwaki M et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2054-8.
10. Ohmachi K, Ando K, Ogura M et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2059-64.
11. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-10.
12. Kahl B, Carbone PP, Bartlett N, Leonard J, Chen L. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer 2010; 116: 106-14.
13. Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43.
14. Robinson KS, Williams ME, Van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-9.
15. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
16. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
17. National Cancer Institute, US National Institutes of Health. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda: National Cancer Institute, US National Institutes of Health, 2006. [Cited 25 Jul 2010.] Available from URL.
18. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
19. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues, 3rd edn. Geneva, Switzerland: International Agency for Research on Cancer (IARC) press; 2001: 119-87.
20. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
21. Owen JS, Melhem M, D'Andrea D, Darwish M. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010; 66: 1039-49.
22. Matthias M, Preiss R, Sohr R, Possinger K. Pharmacokinetics of bendamustin in patients with malignant tumors (Abstract). Proc Am Soc Clin Oncol 1995; 14: 458.
23. Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB. A phase I study of bendamustine hydrochloride administered day 1+2 every 3weeks in patients with solid tumours. Br J Cancer 2007; 96: 1692-8.
24. Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB. A phase I study of bendamustine hydrochloride administered once every 3weeks in patients with solid tumors. Anticancer Drugs 2007; 18: 587-95.
25. Leoni LM, Bailey B, Niemeyer CC et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells (Abstract). AACR Meeting Abstracts 2004; 45: Abstract 1215.
26. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
27. Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90.